Overview

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cycl

Status:
RECRUITING
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
To find out if the combination of repotrectinib and fulvestrant can control the disease in participants with metastatic invasive lobular carcinoma.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Fulvestrant
repotrectinib